Compare AKTX & TOMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKTX | TOMZ |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 13.2M |
| IPO Year | 2014 | 2009 |
| Metric | AKTX | TOMZ |
|---|---|---|
| Price | $8.54 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.50 | N/A |
| AVG Volume (30 Days) | ★ 55.0K | 43.0K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,635,927.00 |
| Revenue This Year | N/A | $111.80 |
| Revenue Next Year | N/A | $52.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.50 |
| 52 Week High | $29.32 | $2.12 |
| Indicator | AKTX | TOMZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 49.39 |
| Support Level | $6.51 | $1.39 |
| Resistance Level | $10.98 | $1.95 |
| Average True Range (ATR) | 0.98 | 0.15 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 11.28 | 73.37 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.